[Retracted] LncRNA-PAX8-AS1 Silencing Decreases Cell Viability, Enhances Apoptosis, and Suppresses Doxorubicin Resistance in Myeloid Leukemia via the miR-378g/ERBB2 Axis

Figure 7

ERBB2 was directly targeted by miR-378g and highly expressed in ADM-resistant AML cells. (a). Venn diagram-based analyses of miR-378g-targeted mRNAs which were predicted through GPL19956 from GSE142700 in GEO predicted from Starbase, and predicted from TargetScan (b) and (c) The expressions of potential miR-378g-targeted mRNAs (EPOR, CDC25B, GNG12, NOTCH2, and ERBB2) in HL60 and HL60/ADM cells were analyzed by qRT-PCR. (d) The sequence alignment between miR-378g and ERBB2 was conducted using TargetScan. (e) and (f) The interaction between miR-378g and ERBB2 was validated by a dual-luciferase reporter assay. (g) and (h). ERBB2 expression in HL60 and HL60/ADM cells was analyzed by qRT-PCR (g), and by Western blot (h), with GAPDH serving as a reference gene.; ; or ; or ; vs. MC; ^∧ vs. IC; ^Δ vs. HL60 (AML: acute myeloid leukemia; ADM: doxorubicin; WT: wild type; MUT: mutant type; qRT-PCR: quantitative reverse transcription-polymerase chain reaction; M: miR-378g mimic; MC: mimic control; I: miR-378g inhibitor; IC: inhibitor control).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)